Novel compounds that synergize with aminoglycoside G418 or eRF3 degraders for translational readthrough of nonsense mutant TP53 and PTEN

The TP53 and PTEN tumour suppressor genes are inactivated by nonsense mutations in a significant fraction of human tumours. TP53 nonsense mutant tumours account for approximately one million new cancer cases per year worldwide. We have screened chemical libraries with the aim of identifying compound...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Angelos Heldin, Matko Cancer, Mireia Palomar-Siles, Susanne Öhlin, Meiqiongzi Zhang, Alexander Sun-Zhang, Anna Mariani, Jianping Liu, Vladimir J.N. Bykov, Klas G. Wiman
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Taylor & Francis Group 2023-12-01
coleção:	RNA Biology
Assuntos:	tp53 pten nonsense mutation novel compounds translational readthrough synergy
Acesso em linha:	http://dx.doi.org/10.1080/15476286.2023.2222250
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!